Arcturus Therapeutics Holdings Inc. - 10-Q Filing
Arcturus Therapeutics reports Q3 2026 results including collaboration revenue and ongoing R&D expenses.
Tickers: $ARCT
Read the full article at SEC EDGAR
Part of the story REGENXBIO Reports Q3 2026 Financial Results Amid Patent Expirations and Litigation Settlement (3 articles)